Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.

Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Dr. Reddy's Laboratories and Alvotech have partnered to co-develop, manufacture, and commercialize a biosimilar of Keytruda ...

Bill Stone, Glenview Trust Company chief investment officer, mentioned his bullish take on Merck (NYSE:MRK) during a recent ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...